Cano Health to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

PR Newswire


MIAMI
, Sept. 12, 2022 /PRNewswire/ — Cano Health Inc. (“Cano” or the “Company”) (NYSE: CANO), a leading value-based primary care provider and population health company, today announced it will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Dr. Marlow Hernandez, Chairman and Chief Executive Officer, and Brian Koppy, Chief Financial Officer, will participate in a fireside chat at 4:05 p.m., Eastern Time.

A live webcast will be accessible through Cano Health’s Investor Relations website at investors.canohealth.com. The webcast will be archived for replay following the conference.

About Cano Health 

Cano Health (NYSE: CANO) is a high-touch, technology-powered healthcare company delivering personalized, value-based primary care to more than 280,000 members. With its headquarters in Miami, Florida, Cano Health is transforming healthcare by delivering primary care that measurably improves the health, wellness, and quality of life of its patients and the communities it serves. Founded in 2009, Cano Health has more than 4,500 employees, and operates primary care medical centers and supports affiliated providers in nine states and Puerto Rico. For more information, visit canohealth.com or investors.canohealth.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cano-health-to-participate-in-the-morgan-stanley-20th-annual-global-healthcare-conference-301622323.html

SOURCE Cano Health, Inc.

ERYTECH Provides Business and Financial Update for the First Half of 2022

ERYTECH Provides
Business
and Financial
Update

for the
First Half
of
20
2
2

Conference call and webcast on Tuesday, September 13, 2022
at 8:30am ET / 02:30pm CEST
        

  • U.S. cell therapy manufacturing facility sold to Catalent
    in April 2022
  • Evaluation
    of
    partnering options ongoing,
    strategic
    initiative expected
    in Q4 2022
  • P
    lans to pursue a BLA submission for
    Graspa
    ® in hypersensitive ALL
    stopped
  • Cash and cash equivalents of €
    53.3
    million ($
    55.8
    million) at the end of
    June
    2022

Cambridge, MA (U.S.)
and Lyon (France)
,
September
12
, 202
2

ERYTECH Pharma
(Nasdaq & Euronext: ERYP),
a
clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today
provided a business
and financial
update
for the first half of
2022
.


2022 has been so far, and will continue to be, a year of deep strategic refoundation for ERYTECH
,said Gil Beyen, Chief Executive Officer of ERYTECH.Earlier this year and as a first result of the strategic review initiated last Fall after the disappointment of our Phase 3 trial in pancreatic cancer, we made a first important step with the saleof our U.S. production facility in Princeton, which significantly improved ERYTECH’s financial prospects and gave us the latitude to continue the transformation of the Company.The recent decision to halt the submission process of our BLA dossier for eryaspase in hypersensitive ALLleads us now to focus on strategic alternatives for ERYTECH. We have prioritized our resources on our most promising preclinical programs, and we are making good progress on partnering discussions, for which we expect to report updates in the last quarter of this year.

Business Highlights

  • U.S. cell therapy manufacturing facility sold to Catalent for a total consideration of USD 44.5 million

In April 2022, ERYTECH sold its commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, to Catalent, for a total consideration of $44.5 million. ERYTECH’s staff at the site of 40 people has been fully transferred to Catalent.

ERYTECH maintained its GMP-approved manufacturing site in Lyon, France and its core expertise to continue innovating in cell therapy.

  • Good progress on strategic review and partnering alternatives

As announced on October 25th 2021, the Company has appointed a specialized advisor to evaluate its strategic and partnering options. After the transaction with Catalent, the Company has continued to evaluate further valuable strategic options to potentially leverage its assets and capabilities in a business combination with a strategic partner. Valuable options are under discussion and the Company expects to give further updates on these strategic initiatives in the 4th quarter of this year.

  • Plans to pursue a BLA submission for
    Graspa
    ® in hypersensitive ALL stopped
    following recent feedbacks and new additional requests from the FDA

Following positive results of a Phase 2 trial, sponsored by the Nordic Organization for Peadiatric Hematology and Oncology (NOPHO), ERYTECH had been in an extended dialogue with the U.S. Food and Drug Administration (FDA) to evaluate the possibility for an approval of Graspa in acute lymphoblastic leukemia (ALL) patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.

A pre-BLA meeting to discuss the submission of a Biologics License Application (BLA) took place in June 2021 after which the Company confirmed its intention to submit a BLA, subject to successful completion of remaining activities, which included the submission of additional information to the FDA, responses to additional data requests, and the submission of the Initial Pediatric Study Plan (iPSP).

The Company submitted its iPSP in July 2022 and received feedback from the FDA in August 2022. After thorough evaluation of this feedback, which included a new request for additional data, and taking into account the changing competitive landscape, the Company decided to halt the BLA process of seeking approval.

  • Resu
    lt
    s of patients enrolled in
    TRYbeCA-2, Phase 2 clinical trial in triple-negative breast cancer (TNBC)
    , reviewed

The TRYbeCA-2 trial evaluated eryaspase in combination with gemcitabine and carboplatin chemotherapy, compared to chemotherapy alone, in metastatic TNBC (first and second lines), with disease control rate as the primary end point of the trial.

Initial target enrollment was approximately 64 evaluable patients but following the disappointing results of eryaspase in the TRYbeCA-1 trial in second-line pancreatic cancer, the Company had decided, in consultation with the trial’s Steering Committee, to stop further enrollment in the trial. A total of 27 patients,11 and 14 evaluable patients in the eryaspase and control arms, respectively, have been finally enrolled.

The trial’s Steering Committee met in September 2022 to review the results of the 25 evaluable patients. No clinical benefit was demonstrated, which could be attributed to the immature closure of the trial and the small number of patients. The treatment was well tolerated.

  • Promising preclinical development with
    ERYCEV

    TM

    , novel red blood cell vesiculation technology

In April 2022, ERYTECH announced the presentation of its novel red blood cell vesiculation technology, ERYCEV, at the 24th Meeting of the European Red Cell Society (ERCS).

RBC-derived extracellular vesicles are formed naturally during senescence and storage of mature RBCs and are a potentially attractive drug delivery system. Vesiculation of RBCs that have already been loaded with active therapeutic compounds utilizing the ERYCAPS® process, entails the potential of producing cargo-loaded RBC-derived extracellular vesicles for the development of novel therapeutic approaches.

ERYCEV results to date illustrate the versatility of ERYTECH’s encapsulation science in RBCs and its potential for leverage in further partnered developments.

1H
202
2
Financial Results

  • Key financial figures for the first half of 2022 compared with the same period of the previous year are summarized below:

In thousands of euros
  1H
202
2

(
6
months)
1H
202
1

(
6
months)
Revenues    —  —
Other income   954 2,270
Net gain on asset sale   24,351  —
Operating income   25,304 2,270
Research and development   (17,300) (23,208)
General and administrative   (7,911) (8,027)
Operating expenses   (
25,211
)
(
31,235
)
Operating
income (
loss
)
  93 (
28,966
)
Financial income   3,370 2,807
Financial expenses   (750) (1,791)
Financial income (loss)   2,620 1,
016
Income tax   (3,737) (2)
Net loss   (1
,024
)
(
27,952
)
  • Net loss for the first half of 2022 was €1.0 million, a €27.0 million improvement over the same period of last year, related mostly to the €24.4 million net gain on the sale of the Princeton facility, while operating expenses of €25.2 million were also showing a €6.0 million decrease (-19%) year-over-year, with a €5.9 million decrease in R&D expenses and a €0.1 million decrease in G&A.
  • Total operating expenses of €25.2 million included an impairment provision of €2.5 million on the Lyon production facility, related to the end of eryaspase operations, and a €1.9 million provision for restructuring, related to the resizing of French operations and staff.
  • Income tax included in 2022 a provision of €3.7 million ($4.1 million), reflecting the best estimate to date of the tax impacts of the capital gain from the sale of the Princeton facility.
  • As of June 30, 2022, ERYTECH had cash and cash equivalents totaling €53.3 million (approximately $55.8 million), compared with €33.7 million as of December 31, 2021. The €19.6 million increase in cash position during the first half of 2022 was the result of the net cash of €37.6 million received from the sale of the Princeton facility, a €20.4 million net cash utilization in operating activities and investing activities (excluding the sale of the Princeton facility) and €2.0 million generated in financing activities, including €3.0 million in pre-funding of the expected 2021 R&D tax credit, while the variation of the U.S. dollar against the euro led to a €0.4 million positive currency exchange impact.
  • The Company has not drawn any tranche on the convertible loan facility (OCABSA) since 2021 and there are no outstanding and unconverted notes. The OCABSA financing line has expired in June 2022.
  • Earlier this year, the company initiated a deep restructuring and cost reduction program, now further intensified with the halt of the BLA process. Considering this ongoing reduction in operating expenses, the Company believes that its current cash position can fund its current programs and planned operating expenses to mid-2024.

Key News Flow and Milestones Expected Over the Next
6
Months

  • Results from the Phase 1 rESPECT Trial of eryaspase in combination with mFOLFIRINOX in first-line pancreatic cancer (2H 2022)
  • Update on partnering discussions (Q4 2022)

First
Half
2022 Conference Call Details

ERYTECH management will hold a conference call and webcast on Tuesday, September 13, 2022, at 8:30am ET / 2:30 pm CEST on the business highlights and financial results for the first half 2022. Gil Beyen, CEO, Eric Soyer, CFO/COO, and Iman El-Hariry, CMO, will deliver a brief presentation, followed by a Q&A session.

The audio call is accessible via the below registering link: https://register.vevent.com/register/BI8faf5b5c094c4e48b5ffac460994e65b

Once registered, participants will receive a unique access code and the call number details to join the teleconference.

The webcast can be followed live online via the link:
https://edge.media-server.com/mmc/p/ejb38tvf

In addition, the replay of the webcast will be available for a period of one year on this same link.


Availability of the
2022 Half-Year
financial report

The Half-Year financial report as of June 30, 2022 has been made available to the public and filed with the Autorité des Marchés Financiers (AMF).

About ERYTECH

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States through a long-term supply agreement with Catalent, operating from ERYTECH’s former GMP facility in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable,
EnterNext
PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.erytech.com

CONTACTS

 

ERYTECH                     
Eric Soyer
CFO & COO
NewCap

Mathilde Bohin / Louis-Victor Delouvrier

Investor relations
Nicolas Merigeau
Media relations

+33 4 78 74 44 38
[email protected]

+33 1 44 71 94 94
[email protected]

 

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding ERYTECH’s business and regulatory strategy and its evaluation of potential strategic transactions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH’s control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the failure to achieve certain regulatory and commercial milestones; (2) the inability to maintain the listing of ERYTECH’s shares on the Nasdaq Global Select market and the Euronext regulated market; (3) changes in applicable laws or regulations; (4) the possibility that ERYTECH may be adversely affected by other economic, business and/or competitive factors; (5) the inability to agree to terms on a long-term supply agreement with Catalent; and (6) other risks and uncertainties indicated from time to time in ERYTECH’s regulatory filings. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2021 Universal Registration Document (Document d’EnregistrementUniversel) filed with the AMF on April 27, 2022 and in the Company’s Annual Report on Form 20-F filed with the SEC on April 28, 2022 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

 

Attachment



Lantronix Announces Acquisition of Uplogix

  • Increases Scale of Out-of-Band Remote Management Solutions Product Offerings
  • Solidifies Lantronix Market Position With Complementary High-End Solutions
  • Drives Significant Engineering Synergies and Leverages Lantronix Sales Motion and Reach
  • Acquisition Expected to Be Accretive to Lantronix GAAP Gross Margins
  • Lantronix Expects Acquisition to Be Accretive to Non-GAAP EPS Within First Six Months Post-Close

IRVINE, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for Intelligent IT and Internet of Things (IoT), today announced its acquisition of Out-of-Band (OOB) management solutions provider, Uplogix Inc., for approximately $8 million in cash with an additional payment of up to $4 million, subject to the achievement of certain revenue targets for Uplogix.

The transaction will bring immediate scale to Lantronix’s OOB remote management solutions, adding a complementary high-end product offering that includes high-margin maintenance and licensing revenues. Lantronix sees significant operating and product development synergies in the combined company and expects the acquisition will be accretive to non-GAAP earnings in the first six months of operations.

OOB network management solutions address the need for more resilient networks for 5G IoT and Edge Computing applications. Gartner Research estimates by 2025, more than 50 percent of enterprise-managed data will be created and processed outside the datacenter or cloud. Lantronix’s investment in OOB technology expands its offering to continue to meet the growing demands of this market.

Lantronix today further reported that it has entered into an amendment to its current Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to provide Lantronix with an additional term loan, in the original principal amount of $5 million, to be used to fund the acquisition of Uplogix and for working capital purposes. The additional term loan bears interest at either term SOFR or the prime rate, at the option of Lantronix, plus a margin that ranges from 3.10 percent to 4.10 percent in the case of term SOFR and 1.50 percent to 2.50 percent in the case of prime rate, depending on Lantronix’s total leverage with a term SOFR floor of 1.50 percent and a prime rate floor of 3.25 percent. 

Uplogix’s last twelve-month revenues were approximately $9 million. Lantronix will update its Fiscal 2023 revenue guidance to include this acquisition in its next quarterly earnings report.

About Lantronix

Lantronix Inc. is a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM), offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware.

Lantronix enables its customers to accelerate time to market and increase operational up-time and efficiency by providing reliable, secure and connected Intelligent Edge IoT and Remote Management Gateway solutions.

Lantronix’s products and services dramatically simplify the creation, development, deployment and management of IoT and IT projects across Robotics, Automotive, Wearables, Video Conferencing, Industrial, Medical, Logistics, Smart Cities, Security, Retail, Branch Office, Server Room, and Datacenter applications. For more information, visit the Lantronix website.

Learn more at the Lantronix blog, which features industry discussion and updates. Follow Lantronix on Twitter, view our YouTube video library or connect with us on LinkedIn.

Discussion of Non-GAAP Financial Measures

Lantronix believes that the presentation of non-GAAP financial information, when presented in conjunction with the corresponding GAAP measures, provides important supplemental information to management and investors regarding financial and business trends relating to the company’s financial condition and results of operations. Management uses the aforementioned non-GAAP measures to monitor and evaluate ongoing operating results and trends to gain an understanding of our comparative operating performance. The non-GAAP financial measures disclosed by the company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations of the non-GAAP financial measures to the financial measures calculated in accordance with GAAP should be carefully evaluated. The non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

Non-GAAP net income consists of net loss excluding (i) share-based compensation and the employer portion of withholding taxes on stock grants, (ii) depreciation and amortization, (iii) interest income (expense), (iv) other income (expense), (v) income tax provision (benefit), (vi) restructuring, severance and related charges, (vii) acquisition related costs, (viii) impairment of long-lived assets, (ix) amortization of purchased intangibles, (x) amortization of manufacturing profit in acquired inventory, (xi) fair value remeasurement of earnout consideration, and (xii) loss on extinguishment of debt.

Non-GAAP EPS is calculated by dividing non-GAAP net loss by non-GAAP weighted-average shares outstanding (diluted). For purposes of calculating non-GAAP EPS, the calculation of GAAP weighted-average shares outstanding (diluted) is adjusted to exclude share-based compensation, which for GAAP purposes is treated as proceeds assumed to be used to repurchase shares under the GAAP treasury stock method.

Guidance on earnings per share growth is provided only on a non-GAAP basis due to the inherent difficulty of forecasting the timing or amount of certain items that have been excluded from the forward-looking non-GAAP measures, and a reconciliation to the comparable GAAP guidance has not been provided because certain factors that are materially significant to Lantronix’s ability to estimate the excluded items are not accessible or estimable on a forward-looking basis without unreasonable effort.

Forward-Looking Statements

This news release contains forward-looking statements, including statements concerning our revenue and earnings expectations for fiscal 2023 and the expected benefits of the acquisition of Uplogix to Lantronix and its stockholders, including expected synergies in the combined company, the accretive nature of the acquisition, and expected future operating results of the combined company. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. We have based our forward-looking statements on our current expectations and projections about trends affecting our business and industry and other future events. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties that could cause our results or experiences, or future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this news release. Other factors which could have a material adverse effect on our operations and future prospects or which could cause actual results to differ materially from our expectations include, but are not limited to: our ability to integrate the acquired business successfully and achieve the anticipated benefits; risks relating to any unforeseen liabilities of the acquired business; the outcome of any legal proceedings that may be instituted against any of the parties in connection with the acquisition; any loss of management or key personnel; the impact of the COVID-19 pandemic, including the emergence of new more contagious and/or vaccine-resistant strains of the virus and the impact of vaccination efforts, including the efficacy and public acceptance of vaccinations, on our business, employees, supply and distribution chains and the global economy; the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; our ability to successfully convert our backlog and current demand; our ability to mitigate any disruption in our and our suppliers’ and vendors’ supply chains due to the COVID-19 pandemic, the war between Ukraine and Russia or other causes; our ability to successfully implement our acquisitions strategy or integrate future acquired companies; uncertainty as to the future profitability of acquired businesses, and delays in the realization of, or the failure to realize, any accretion from future acquisition transactions; acquiring, managing and integrating new operations, businesses or assets, and the associated diversion of management attention or other related costs or difficulties; our ability to continue to generate revenue from products sold into mature markets; our ability to develop, market, and sell new products; our ability to succeed with our new software offerings; fluctuations in our revenue due to the project-based timing of orders from certain customers; unpredictable timing of our revenues due to the lengthy sales cycle for our products and services and potential delays in customer completion of projects; our ability to accurately forecast future demand for our products; delays in qualifying revisions of existing products; constraints or delays in the supply of, or quality control issues with, certain materials or components; difficulties associated with the delivery, quality or cost of our products from our contract manufacturers or suppliers; risks related to the outsourcing of manufacturing and international operations; difficulties associated with our distributors or resellers; intense competition in our industry and resultant downward price pressure; rises in inventory levels and inventory obsolescence; undetected software or hardware errors or defects in our products; cybersecurity risks; our ability to obtain appropriate industry certifications or approvals from governmental regulatory bodies; changes in applicable U.S. and foreign government laws, regulations, and tariffs; our ability to protect patents and other proprietary rights and avoid infringement of others’ proprietary technology rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; our ability to attract and retain qualified management; and any additional factors included in our Report on Form 10-K for the fiscal year ended June 30, 2022, filed with the Securities and Exchange Commission (the “SEC”) on August 29, 2022, including in the section entitled “Risk Factors” in Item 1A of Part I of that report, and in our other public filings with the SEC. In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, investors are cautioned not to place undue reliance on any forward-looking statements. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of the Nasdaq Stock Market LLC. If we do update or correct any forward-looking statements, investors should not conclude that we will make additional updates or corrections
© 2022 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark.

Lantronix Investor Relations Contact:        
Jeremy Whitaker
Chief Financial Officer
[email protected]



Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects


The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects


Independent Data Monitoring Board to review interim data from approximately 200 initial subjects

SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects.

“We are very pleased to reach this trial milestone and eagerly await the next DSMB meeting later this month,” David J. Marguglio, Adamis’ CEO stated. “This interim meeting is significant as it will mark the first time the DSMB evaluates statistical measures of efficacy for Tempol.”

The Data Safety Monitoring Board (DSMB) is comprised of infectious disease experts who independently review the unblinded trial data and make recommendations. The DSMB previously met to evaluate the clinical and safety data from interim analyses in March and June 2022, and both times recommended that the study continue without modification. At the September meeting, the DSMB plans to evaluate the primary efficacy endpoint, the sustained resolution of COVID-19 symptoms, as well as safety in individuals who are at high risk for disease progression for approximately 190 subjects.

If analysis of the interim clinical data showed significant efficacy, the DSMB may recommend stopping the trial because it has already demonstrated statistical significance. If the interim data indicated no efficacy on the primary endpoint, the DSMB would likely recommend stopping the trial for futility. Under that outcome, the Company would begin analyzing the then unblinded data to determine if there were efficacy on the secondary endpoints. If positive efficacy trends are observed on the primary endpoint in favor of Tempol, but statistical significance is not reached, the DSMB may recommend continuing the trial and enrolling additional patients to further power the study.

Ron Moss, M.D., Chief Medical Officer of Adamis added, “If either the interim data or the final clinical data shows positive results, we would submit a clinical study report to the FDA and request a meeting to discuss the findings and the potential for Emergency Use Authorization. The Agency has approved two oral antivirals under EUA for outpatients with COVID-19. Regardless of what form COVID-19 takes going forward, we believe there will always be a medical need and large market for new effective therapeutics.”


About the Trial

“A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection” was designed to enroll approximately 248 high risk subjects with early COVID-19 infection age 18 years of age and older. The primary endpoint is the rate of sustained clinical resolution between Tempol and the standard of care versus placebo and the standard of care at Day 14. In addition to the primary endpoint, a number of secondary endpoints will be reviewed including, but not limited to, changes in inflammatory markers, hospitalizations, and all cause of mortality. Eligible subjects with positive COVID-19 infection within five days of study entry plus at least one co-morbidity were randomized one-to-one to receive either Tempol or placebo. Co-morbidities include age of 65 or older, hypertension, diabetes, obesity, cancer, immunodeficiency and in the opinion of the investigator the risk factor is not acutely life-threatening. Patients randomized to Tempol received 800mg daily in two divided oral doses of 400mg capsules for up to 21 days. Similarly, placebo capsules were administered twice daily to subjects in the placebo group for up to 21 days. Additional information about the trial can be found on www.clinicaltrials.gov using the identifier NCT04729595.


About Tempol

Tempol is a redox cycling nitroxide that promotes the metabolism of many reactive oxygen species and improves nitric oxide bioavailability. It has been studied extensively in animal models of oxidative stress and inflammation. Preclinical studies of Tempol have shown it to have anti-inflammatory and antioxidant activity. Adamis has licensed exclusive rights under certain patents, patent applications and related know-how relating to Tempol for certain licensed fields including the fields of COVID-19 infection, asthma, respiratory syncytial virus infection, and influenza infection, as well as a therapeutic for radiation-induced dermatitis.


About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s SYMJEPI® (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company’s ZIMHI® (naloxone) Injection product is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway. For additional information about Adamis Pharmaceuticals, please visit our website and follow us on Twitter and LinkedIn.


Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: statements concerning the Company’s Phase 2/3 clinical trial for Tempol; statements concerning the activities and process of the DSMB and the timing and outcome of that process; the Company’s beliefs concerning the mechanisms of action, safety and effectiveness of Tempol and that Tempol addresses an unmet medical need; the timing, progress or results of the Company’s Phase 2/3 clinical trial for Tempol or other studies or trials relating to Tempol; the Company’s beliefs concerning the ability of its products and product candidates to compete successfully in the market; the Company’s beliefs concerning the benefits, enforceability, and extent of intellectual property rights and protection afforded by patents and patent applications that it owns or has licensed, including those relating to Tempol; the Company’s ability to successfully commercialize the products and product candidates, itself or through commercialization partners; and other statements concerning the Company’s future operations and activities. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, which may cause Adamis’ actual results to be materially different from the results anticipated by such forward-looking statements. There are no assurances concerning the timing or outcome of, or recommendations resulting from, any future meeting of the DSMB. There can be no assurances regarding the timing, progress or outcome of trials or studies relating to Tempol, or that Tempol will be found to be safe and effective in the treatment of COVID-19 or any other indication. In addition, forward-looking statements concerning our anticipated future activities assume that we have sufficient funding to support such activities and continue our operations and planned activities. Statements in this press release concerning future events depend on several factors beyond the Company’s control, including the absence of unexpected developments or delays, market conditions, the availability of sufficient funding, and the regulatory approval process. We cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s website at http://www.sec.gov.


Contacts

Adamis Investor Relations
Robert Uhl
Managing Director
ICR Westwicke
619.228.5886
[email protected]



Nasdaq Announces End of Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date August 31, 2022

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) — At the end of the settlement date of August 31, 2022, short interest in 3,449 Nasdaq Global MarketSM securities totaled 10,037,516,423 shares compared with 10,108,978,643 shares in 3,454 Global Market issues reported for the prior settlement date of August 15, 2022. The end of August short interest represent 3.13 days average daily Nasdaq Global Market share volume for the reporting period, compared with 2.71 days for the prior reporting period.

Short interest in 2,085 securities on The Nasdaq Capital MarketSM totaled 2,014,832,656 shares at the end of the settlement date of August 31, 2022 compared with 2,099,022,526 shares in 2,100 securities for the previous reporting period. This represents a 1.57 day average daily volume; the previous reporting period’s figure was 1.48.

In summary, short interest in all 5,534 Nasdaq® securities totaled 12,052,349,079 shares at the August 31, 2022 settlement date, compared with 5,554 issues and 12,208,001,169 shares at the end of the previous reporting period. This is 2.68 days average daily volume, compared with an average of 2.37 days for the previous reporting period.

The open short interest positions reported for each Nasdaq security reflect the total number of shares sold short by all broker/dealers regardless of their exchange affiliations. A short sale is generally understood to mean the sale of a security that the seller does not own or any sale that is consummated by the delivery of a security borrowed by or for the account of the seller.

For more information on Nasdaq Short interest positions, including publication dates, visit http://www.nasdaq.com/quotes/short-interest.aspx or http://www.nasdaqtrader.com/asp/short_interest.asp.

About Nasdaq: 

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

NDAQO

Media Contact:

Emily Pan
[email protected]

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/52e4cd7b-b7a8-4645-96a0-2b48060bde92



3D Systems Announces Appointment of Andrew Johnson as Chief Corporate Development Officer

ROCK HILL, S.C., Sept. 12, 2022 (GLOBE NEWSWIRE) — Today, 3D Systems (NYSE:DDD) announced that Andrew Johnson, the company’s executive vice president, chief legal officer, is taking on expanded responsibilities as chief corporate development officer. In this role, he will not only lead the company’s mergers and acquisitions but will also lead the establishment of new strategic partnerships in support of the company’s expanding business needs. Mr. Johnson has been with 3D Systems for more than 16 years, and during this time has led over 60 M&A transactions for the company, and has played a key role in the development of several strategic partnerships. His strategic vision, experience, and knowledge of the additive manufacturing industry make him well suited to take on this expanded responsibility as chief corporate development officer, in addition to his current role as chief legal officer. Mr. Johnson holds a BA from Miami University, an MBA from the Ross School of Business at the University of Michigan, and a JD from the University of Virginia.

“Our core strength as a company, one that differentiates us from our competitors, is our relentless application focus in meeting our customers’ most important challenges,” said Dr. Jeffrey Graves, president and CEO, 3D Systems. “To be effective in this approach, it is essential for us to be the leader in bringing to bear a broad range of core printing technologies, from metals to polymers and biologics, in combination with market-leading materials and software solutions. To do this on an ever-larger scale, we must increasingly seek strategic partnerships, ranging from basic technology to commercial channels to market. This activity is essential in order to capitalize on the full spectrum of exciting opportunities that are opening ahead of us, as additive manufacturing enters full-scale production environments. Andy’s experience and knowledge of our company and the industry broadly position him very well for success in this expanded role.”   

Mr. Johnson’s responsibilities will span the entire range of the company’s interests. One of the key emerging areas that he will be addressing is the increasing partnership opportunities 3D Systems now has in regenerative medicine. With the technical progress achieved by 3D Systems’ regenerative medicine team, under the leadership of Chuck Hull, chief technology officer for regenerative medicine, and in partnership with United Therapeutics, along with the acquisitions of Allevi and Volumetric Biotechnologies, the company possesses unique capabilities that are needed to pursue an increasing number of new biologic applications. To capitalize on this potential, Mr. Johnson will explore application partnerships that could accelerate the company’s growth in these new and exciting markets.

Forward-Looking Statements

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or revise any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law.

About 3D Systems

More than 35 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading additive manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction – empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials, and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace & defense, automotive, and durable goods. More information on the company is available at www.3dsystems.com.

Investor Contact: [email protected]
Media Contact: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b20070fd-a0ac-4f23-93a9-4aba4540cad5



Superior Group of Companies to Participate in the Singular Autumn Equinox Virtual Webinar

SEMINOLE, Fla., Sept. 12, 2022 (GLOBE NEWSWIRE) —  Superior Group of Companies, Inc. (NASDAQ: SGC) today announced that Michael Benstock, Chief Executive Officer, and Michael Koempel, Chief Financial Officer, will participate in the Singular Autumn Equinox Virtual Webinar on Thursday, September 15, 2022. Management will present at 10:00 a.m. Eastern Time for approximately 30 minutes followed by approximately 15 minutes of moderated Q&A, and the webinar will be available on the investor relations presentations page of the company’s website at https://ir.superiorgroupofcompanies.com/presentations.

About Superior Group of Companies, Inc. (SGC):

Superior Group of Companies, established in 1920, is a combination of companies that help our customers unlock the power of their brands by creating extraordinary brand engagement experiences for their employees and customers. SGC’s commitment to service, technology, quality and value-added benefits, as well as our financial strength and resources, provides unparalleled support for our customers’ diverse needs while embracing a “Customer 1st, Every Time!” philosophy and culture in all of our business segments. Visit www.superiorgroupofcompanies.com for more information.



Contact:
Investor Relations
[email protected]

Planet Reports Financial Results for Second Quarter of Fiscal Year 2023

Planet Reports Financial Results for Second Quarter of Fiscal Year 2023

Delivers Record Second Quarter Revenue of $48.5 Million, up 59% Year-over-Year

Expands YoY Second Quarter GAAP Gross Margin Expansion to 48% from 35%

Increases Full Year Revenue Guidance for FY’23 to 42% YoY Growth at the Midpoint

SAN FRANCISCO–(BUSINESS WIRE)–
Planet Labs PBC (NYSE: PL) (“Planet” or the “Company”), a leading provider of daily data and insights about Earth, today announced financial results for its fiscal second quarter for the period ended July 31, 2022, demonstrating accelerated growth and momentum of its unique data subscription business.

“Planet’s results for the second quarter exceeded expectations across the board and demonstrate the continued acceleration of our growth rate and robust demand for our unique Earth data solutions,” said Will Marshall, Planet’s Co-Founder, Chief Executive Officer and Chairperson. “In addition to the strength of our revenue and gross margin expansion during Q2, we’re also pleased with the meaningful increase in net dollar retention rate, which we believe demonstrates that our investments in product and customer success are yielding results.”

Ashley Johnson, Planet’s Chief Financial and Operating Officer, added, “For the second quarter of fiscal year 2023, we delivered $48.5 million in revenue, a growth rate of 59% year-over-year, expanded Non-GAAP Gross Margin to 52%, and ended the quarter with $458 million of cash, cash equivalents and short-term investments. Q2 was an excellent quarter for Planet, and we’re pleased with the continued momentum that we’re seeing in the business.”

Fiscal Second Quarter 2022 Financial and Key Metric Highlights:

  • Second quarter revenue increased 59% year-over-year to $48.5 million.
  • Percent of Recurring Annual Contract Value (ACV) for the second quarter was 93%.
  • End of Period (EoP) Customer Count increased 17% year-over-year to 855 customers.
  • Net dollar retention rate for the quarter was 125%, while net dollar retention rate with winbacks was 127%.
  • Second quarter gross margin expanded to 48%, compared to 35% in the second quarter of fiscal year 2022. Second quarter Non-GAAP Gross Margin(1) expanded to 52%, compared to 36% in the second quarter of fiscal year 2022.
  • Ended the quarter with $458 million in cash, cash equivalents and short-term investments.

(1) Please see “Planet’s Use of Non-GAAP Financial Measures” below for a discussion on how Planet calculates the non-GAAP financial measures presented herein. In addition, please find below a reconciliation to the most directly comparable U.S. GAAP financial measure

Recent Business Highlights:

Growing Customer and Partner Relationships:

  • German Federal Government: Planet announced that it is providing the German Federal Agency for Cartography and Geodesy (BKG) with daily, high-resolution satellite data for a huge variety of use cases, including crisis response, environmental management and nature conservation, as well as forest and agricultural monitoring. This is a pioneering contract – a country-wide partnership through which employees of more than 400 German federal institutions can gain access to Planet’s data to help promote public and civil safety throughout the entire Federal Republic of Germany. This engagement follows an assessment by the central government that determined that Planet’s data can help address the needs of the entire German Federal government.
  • Organic Valley: Planet announced that it has completed a successful pilot program with Organic Valley, the organic food brand and independent cooperative of organic farmers. The program utilized satellite technology to efficiently measure pasture health on dairy farms. By using Planet’s satellite data, participating Organic Valley farmers accessed reports created by the cooperative regarding their pastures which helped them assess pasture quality, thereby supporting herd nutrition, and contributing to sustainable agricultural practices like regenerative rotational grazing.
  • NMSLO: The New Mexico State Land Office further expanded their relationship with Planet. Using Planet’s road change detection analytics, the NMSLO has been able to detect roads that were created on protected land and has identified trespass violations resulting in up to $1 million in fines thus far. After the devastating beginning of the 2022 wildfire season, the New Mexico State Land Office has now begun using SkySat to monitor burn scars and severity, allowing the state to plan for potential flooding and debris flows along with mitigation efforts to restore the land.

Supporting Ukraine Response:

  • Planet is supporting critical efforts in multiple areas by providing imagery to governments, aid and relief organizations, think tanks and the media. Planet continued that important work in Q2.
  • NASA Harvest: The team at NASA Harvest, NASA’s food security and agriculture program, used Planet data to complete a country-wide assessment of the health of grain in Ukraine and its effect on global grain supplies. As of August 2022, the Harvest team found that more cropland than was initially expected has been harvested and planted along both the Russian-occupied and Ukrainian-held territories. The team is also currently estimating a higher production out of the region than other publicly-sourced estimates.
  • Windward: Maritime AI company Windward, when combining their AI-powered behavioral analytics models with Planet’s daily imagery, found vessels engaging in dark activities and ship-to-ship (STS) operations in the Kerch Strait in June 2022 as part of what appeared to be a coordinated effort to launder grain allegedly stolen from Ukraine. The report found a 160% increase in dark activity in the Black Sea YoY, with 73% of those cases occurring after the war started.

Building New Technologies and Missions:

  • NASA CSP: Planet announced that it is supporting NASA’s Communication Services Project, or “CSP”, alongside two partners, SES Government Solutions and Telesat Government Solutions, to demonstrate real-time space-to-space connectivity solutions from Planet’s LEO satellites to other in-space communication satellites operated by SES and Telesat. Planet will work to demonstrate its state-of-the art communication technology stack involving real-time satellite connectivity for NASA’s CSP, with the goal of further building its relationship with the agency and accelerating the deployment of low latency solutions for Planet customers.

Impact and Education:

  • Planet’s robust Education and Research (E&R) program continues to enable new use cases of Planet’s data and better forecasts of resultant environmental, economic and geopolitical effects. For example, researchers at Duke University and the California Air Resource Board recently used Planetscope data combined with novel AI analytical techniques to identify dangerous levels of fine particulate air pollution in Delhi and Beijing so that in the future such methods could be used to more efficiently mitigate the effects of poor air quality in cities around the world.

Financial Outlook

For the third quarter of fiscal year 2023, Planet expects revenue to be in the range of approximately $45 million to $48 million, representing approximately 47% year-over-year growth at the midpoint. Non-GAAP Gross Margin is expected to be between approximately 47% to 49%. Adjusted EBITDA is expected to be between approximately ($22) million and ($20) million. Capital Expenditure as a Percentage of Revenue is expected to be between approximately 16% and 19% of revenue for the third quarter.

For fiscal year 2023, Planet has increased its revenue outlook and expects it to be in the range of approximately $182 million to $190 million, representing approximately 42% growth at the midpoint. Non-GAAP Gross Margin is expected to be between approximately 49% to 51%. Adjusted EBITDA is expected to be between approximately ($68) million and ($60) million. Capital Expenditure as a Percentage of Revenue is expected to be between approximately 13% to 15% for the full fiscal year 2023.

Planet has not reconciled its Non-GAAP Gross Margin outlook, which is derived from Non-GAAP Gross Profit, or Adjusted EBITDA outlook to their most directly comparable GAAP measures (gross profit and net loss, respectively) because certain items that impact gross profit and net loss, such as stock-based compensation expenses and (in the case of Adjusted EBITDA) depreciation and amortization, are uncertain or out of Planet’s control and cannot be reasonably predicted. The actual amount of these expenses during the third quarter of fiscal year 2023 and fiscal year 2023 will have a significant impact on Planet’s future GAAP financial results. Accordingly, a reconciliation of Non-GAAP Gross Margin outlook and Adjusted EBITDA outlook to gross profit margin and net loss, respectively, is not available without unreasonable efforts.

The foregoing forward-looking statements reflect Planet’s expectations as of today’s date. Given the number of risk factors, uncertainties and assumptions discussed below, actual results may differ materially.

Webcast and Conference Call Information

Planet will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT today, September 12, 2022. The webcast can be accessed at www.planet.com/investors/. A replay will be available approximately 2 hours following the event. If you would prefer to register for the conference call, please go to the following link: https://www.netroadshow.com/events/login?show=18e20112&confId=40434. You will then receive your access details via email.

Additionally, a supplemental presentation has been made available on Planet’s investor relations page.

Investor Day 2022

Planet plans to host an Investor Day in San Francisco on Wednesday, October 12, 2022. The program is set to begin at 12:00 p.m. Eastern Time / 9:00 a.m. Pacific Time. The Investor Day program will feature sessions led by management, including Will Marshall, Co-Founder and CEO; Kevin Weil, President of Product and Business; and Ashley Johnson, Chief Financial Officer and Chief Operating Officer. The event will be accessible virtually. To attend virtually, please check planet.com/investors the week of October 10th. A recording will be available on Planet’s Investor Relations website shortly after the event.

About Planet Labs PBC

Planet is a leading provider of global, daily satellite imagery and geospatial solutions. Planet is driven by a mission to image the world every day, and make change visible, accessible and actionable. Founded in 2010 by three NASA scientists, Planet designs, builds, and operates the largest Earth observation fleet of imaging satellites, capturing over 30 TB of data per day. Planet provides mission-critical data, advanced insights, and software solutions to over 800 customers, comprising the world’s leading agriculture, forestry, intelligence, education and finance companies and government agencies, enabling users to simply and effectively derive unique value from satellite imagery. Planet is a public benefit corporation trading on the New York Stock Exchange as PL. To learn more visit www.planet.com and follow us on Twitter.

Planet’s Use of Non-GAAP Financial Measures

This press release includes Non-GAAP Gross Profit, Non-GAAP Gross Margin, which is derived from Non-GAAP Gross Profit, Adjusted EBITDA, certain non-GAAP expenses described further below, Non-GAAP Loss from Operations, Non-GAAP Net Loss and Non-GAAP Net Loss per Diluted Share, which are non-GAAP performance measures that the Company uses to supplement its results presented in accordance with U.S. GAAP. The Company believes these non-GAAP financial measures are useful in evaluating its operating performance, as they are similar to measures reported by the Company’s public competitors and are regularly used by analysts, institutional investors, and other interested parties in analyzing operating performance and prospects. Further, the Company believes such non-GAAP measures are helpful in highlighting trends in the Company’s operating results because they exclude items that are not indicative of the Company’s core operating performance. In addition, the Company includes these non-GAAP financial measures because they are used by management to evaluate the Company’s core operating performance and trends and to make strategic decisions regarding the allocation of capital and new investments.

Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, as a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. GAAP. Specifically, these measures should not be considered as an alternative to cost of revenue, gross profit, operating expenses, operating income, net income, earnings per share, or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of liquidity. The non-GAAP financial measures presented are not based on any standardized methodology prescribed by U.S. GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Further, the non-GAAP financial measures presented exclude stock-based compensation expenses, which has recently been, and will continue to be for the foreseeable future, a significant recurring expense for the Company’s business and an important part of its compensation strategy.

Planet calculates these non-GAAP financial measures as follows:

Non-GAAP Gross Profit and Non-GAAP Gross Margin: The Company defines and calculates Non-GAAP Gross Profit as gross profit adjusted for stock-based compensation expenses and amortization of acquired intangible assets classified as cost of revenue, and Non-GAAP Gross Margin as the percentage of Non-GAAP Gross Profit to revenue.

Non-GAAP Expenses: The Company defines and calculates Non-GAAP cost of revenue, Non-GAAP research and development expenses, Non-GAAP sales and marketing expenses, and Non-GAAP general and administrative expenses as, in each case, the corresponding U.S. GAAP financial measure (cost of revenue, research and development expenses, sales and marketing expenses, and general and administrative expenses) adjusted for stock-based compensation expenses and amortization of acquired intangible assets that are classified within each of the corresponding U.S. GAAP financial measures.

Non-GAAP Loss from Operations: The Company defines and calculates Non-GAAP Loss from Operations as loss from operations adjusted for stock-based compensation expenses and amortization of acquired intangible assets.

Non-GAAP Net Loss and Non-GAAP Net Loss per Diluted Share: The Company defines and calculates Non-GAAP Net Loss as net loss adjusted for stock-based compensation expenses, amortization of acquired intangible assets and the tax effects of the adjustments. The Company defines and calculates Non-GAAP Net Loss per Diluted Share as Non-GAAP Net Loss divided by diluted weighted-average common shares outstanding.

Adjusted EBITDA: The Company defines and calculates Adjusted EBITDA as net loss before the impact of interest income and expense, income tax expense and depreciation and amortization, and further adjusted for the following items: stock-based compensation; change in fair value of convertible notes and warrant liabilities; gain or loss on the extinguishment of debt; and non-operating income and expenses such as foreign currency exchange gain or loss.

Other Key Metrics

Percent of Recurring ACV: The Company defines Annual Contract Value (“ACV”) for contracts of one year or greater as the total amount of value that a customer has contracted to pay for the most recent 12 month period for the contract. For short-term contracts (contracts less than 12 months), ACV is equal to total contract value. The Company defines Percent of Recurring ACV as the dollar value of all data subscription contracts and the committed portion of usage-based contracts divided by the total dollar value of all contracts in its ACV Book of Business at a specific point in time. The Company defines ACV Book of Business as the sum of the ACV of all contracts that are active on the last day of the period pursuant to the effective dates and end dates of such contracts. The Company believes Percent of Recurring ACV is a useful metric for investors and management to track as it helps to illustrate how much of its revenue comes from customers that have the potential to renew their contracts over multiple years rather than being one-time in nature. In calculating Percent of Recurring ACV, management applies judgment as to which customers have an active contract at a period end for the purpose of determining ACV Book of Business, which is used as part of the calculation of Percent of Recurring ACV.

EoP Customer Count: The Company defines EoP Customer Count as the total count of all existing customers at the end of the period. It defines existing customers as customers with an active contract with the Company at the end of the reported period. For the purpose of this metric, the Company defines a customer as a distinct entity that uses its data or services. The Company sells directly to customers, as well as indirectly through its partner network. If a partner does not provide the end customer’s name, then the partner is reported as the customer. Each customer, regardless of the number of active opportunities with the Company, is counted only once. For example, if a customer utilizes multiple products of the Company, the Company only counts that customer once for purposes of EoP Customer Count. A customer with multiple divisions, segments, or subsidiaries are also counted as a single unique customer based on the parent organization or parent account. The Company believes EoP Customer Count is a useful metric for investors and management to track as it is an important indicator of the broader adoption of its platform and is a measure of its success in growing its market presence and penetration. In calculating EoP Customer Count, management applies judgment as to which customers are deemed to have an active contract in a period, as well as whether a customer is a distinct entity that uses the Company’s data or services.

Net Dollar Retention Rate including Winbacks: The Company defines Net Dollar Retention Rate including winbacks as the percentage of ACV generated by existing customers and winbacks in a given period as compared to the ACV of all contracts at the beginning of the fiscal year from the same set of existing customers. A winback is a previously existing customer who was inactive at the start of the fiscal year, but has reactivated during the same fiscal year period. The reactivation period must be within 24 months from the last active contract with the customer; otherwise, the customer is assumed as a new customer. We believe this metric is useful to investors as it captures the value of customer contracts that resume business with the Company after being inactive and thereby provides a quantification of the Company’s ability to recapture lost business. Management applies judgment in determining the value of active contracts in a given period, as set forth in the definition of ACV above. Management uses this metric to understand the adoption of our products and long-term customer retention, as well as the success of marketing campaigns and sales initiatives in re-engaging inactive customers.

Capital Expenditures as a Percentage of Revenue: The Company defines capital expenditures as purchases of property and equipment plus capitalized internally developed software development costs, which are included in our statements of cash flows from investing activities. The Company defines Capital Expenditures as a Percentage of Revenue as the total amount of capital expenditures divided by total revenue in the reported period. Capital Expenditures as a Percentage of Revenue is a performance measure that we use to evaluate the appropriate level of capital expenditures needed to support demand for the Company’s data services and related revenue, and to provide a comparable view of the Company’s performance relative to other earth observation companies, which may invest significantly greater amounts in their satellites to deliver their data to customers. The Company uses an agile space systems strategy, which means we invest in a larger number of significantly lower cost satellites and software infrastructure to automate the management of the satellites and to deliver the Company’s data to clients. As a result of the Company’s strategy and business model, the Company’s capital expenditures may be more similar to software companies with large data center infrastructure costs. Therefore, the Company believes it is important to look at the level of capital expenditure investments relative to revenue when evaluating the Company’s performance relative to other earth observation companies or to other software and data companies with significant data center infrastructure investment requirements. The Company believes Capital Expenditures as a Percentage of Revenue is a useful metric for investors because it provides visibility to the level of capital expenditures required to operate the Company and the Company’s relative capital efficiency.

Forward-looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the Company’s ability to capture market opportunity; whether and when the Company will be able to execute on its growth initiatives; whether the Company will realize any of the potential benefits from strategic acquisitions; whether the Company will be able to successfully build or deploy its satellites, including new satellites that are in development; whether the Company will be able to continue to invest in scaling its sales organization and expanding its software engineering capabilities; how the Company will execute on its partnerships and contracts and how the Company’s partners and customers will utilize the Company’s data; and the Company’s financial outlook. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “seek,” “may,” “will,” “could,” “can,” “should,” “would,” “believes,” “predicts,” “potential,” “strategy,” “opportunity,” “aim,” “continue” and similar expressions or the negative thereof, or discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals, are intended to identify such forward-looking statements. Forward-looking statements are based on the Company’s management’s beliefs, as well as assumptions made by, and information currently available to them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. Factors which may cause actual results to differ materially from current expectations include, but are not limited to: the Company’s limited operating history making it difficult to predict its future operating results; the Company’s expectations that its operating expenses will increase substantially for the foreseeable future; whether the market for the Company’s products and services that is built upon its data set, which has not existed before, will grow as expected; the Company’s ability to manage its growth effectively; whether current customers or prospective customers adopt the Company’s platform; whether the Company will be able to compete effectively with the increasing competition in its market from commercial entities and governments; the Company’s ability to continue to capture certain high-value government procurement contracts; the Company’s ability to obtain or maintain regulatory approvals and/or adhere to regulatory requirements, including those related to the Company’s ability to operate as a government contractor with the required security clearances; changes in government policies regarding the use of commercial data or satellite operators, material delay or cancellation of certain government programs, government spending authorizations and budgetary priorities; changes in general global economic conditions, the Company’s operations (including the development, launch and operation of satellites) or other unforeseen circumstances that may alter or delay the Company’s ability to perform under future contracts and may impact the renewal and final profitability of such contracts; the cancellation of contracts by the government and any potential contract options which may or may not be exercised by the government in the future; whether the Company is subject to any risks as a result of its global operations, including, but not limited to, being subject to any hostile actions by a government or other state actor; the Company’s international operations creating business and economic risks that could impact its operations and financial results; the interruption or failure of the Company’s satellite operations, information technology infrastructure or loss of its data storage, whether by cyber-attacks or other adverse events that limit its ability to perform its daily operations effectively and provide its products and services; whether the Company experiences any adverse events, such as delayed launches, launch failures, its satellites failing to reach their planned orbital locations, its satellites failing to operate as intended, being destroyed or otherwise becoming inoperable, the cost of satellite launches significantly increasing and/or satellite launch providers not having sufficient capacity; the Company’s satellites not being able to capture Earth images due to weather, natural disasters or other external factors, or as a result of its constellation of satellites having restrained capacity; if the Company is unable to develop and release product and service enhancements to respond to rapid technological change, or to develop new designs and technologies for its satellites, in a timely and cost-effective manner; downturns or volatility in general economic conditions, including as a result of the current COVID-19 pandemic, including any variants thereof, or any other outbreak of an infectious disease; the effects of acts of terrorism, war or political instability, both domestically and internationally, including the current events involving Russia and Ukraine, changes in laws and regulations, or the imposition of economic or trade sanctions affecting international commercial transactions; the loss of one or more of the Company’s key personnel, or its failure to attract, hire, retain and train other highly qualified personnel in the future; the Company’s ability to raise adequate capital, including on acceptable terms, to finance its business strategies; how rules and regulations in the Company’s highly regulated industry may impact its business; if the Company fails to maintain effective internal controls over financial reporting at a reasonable assurance level; and the other factors described under the heading “Risk Factors” in the Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission (SEC) and any subsequent filings with the SEC the Company may make. Copies of each filing may be obtained from the Company or the SEC (including the Quarterly Report on Form 10-Q filed September 12, 2022). All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date of this press release. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances. The Company’s results for the quarter ended July 31, 2022 are not necessarily indicative of its operating results for any future periods.

PLANET

CONSOLIDATED BALANCE SHEETS (unaudited)

 

(In thousands, except share and par value amounts)

July 31, 2022

 

January 31, 2022

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

262,061

 

 

$

490,762

 

Short-term investments

 

195,630

 

 

 

 

Accounts receivable, net

 

26,116

 

 

 

44,373

 

Prepaid expenses and other current assets

 

20,298

 

 

 

16,385

 

Total current assets

 

504,105

 

 

 

551,520

 

Property and equipment, net

 

120,921

 

 

 

133,280

 

Capitalized internal-use software, net

 

11,218

 

 

 

10,768

 

Goodwill

 

103,219

 

 

 

103,219

 

Intangible assets, net

 

13,077

 

 

 

14,197

 

Restricted cash, non-current

 

5,648

 

 

 

5,743

 

Operating lease right-of-use assets

 

5,646

 

 

 

 

Other non-current assets

 

4,060

 

 

 

2,714

 

Total assets

$

767,894

 

 

$

821,441

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities

 

 

 

Accounts payable

$

2,189

 

 

$

2,850

 

Accrued and other current liabilities

 

47,821

 

 

 

48,823

 

Deferred revenue

 

52,083

 

 

 

64,233

 

Liability from early exercise of stock options

 

14,342

 

 

 

16,135

 

Operating lease liabilities, current

 

5,845

 

 

 

 

Total current liabilities

 

122,280

 

 

 

132,041

 

Deferred revenue

 

 

 

 

3,579

 

Deferred hosting costs

 

11,026

 

 

 

12,149

 

Public and private placement warrant liabilities

 

17,836

 

 

 

23,224

 

Deferred rent

 

 

 

 

798

 

Operating lease liabilities, non-current

 

1,670

 

 

 

 

Other non-current liabilities

 

1,439

 

 

 

1,405

 

Total liabilities

 

154,251

 

 

 

173,196

 

Commitments and contingencies

 

 

 

Stockholders’ equity

 

 

 

Common stock

 

27

 

 

 

27

 

Additional paid-in capital

 

1,472,119

 

 

 

1,423,151

 

Accumulated other comprehensive income

 

2,716

 

 

 

2,096

 

Accumulated deficit

 

(861,219

)

 

 

(777,029

)

Total stockholders’ equity

 

613,643

 

 

 

648,245

 

Total liabilities and stockholders’ equity

$

767,894

 

 

$

821,441

 

PLANET

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

 

 

Three Months Ended July 31,

 

Six Months Ended July 31,

(In thousands, except share and per share amounts)

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Revenue

$

48,450

 

 

$

30,406

 

 

$

88,577

 

 

$

62,363

 

Cost of revenue

 

24,977

 

 

 

19,820

 

 

 

48,605

 

 

 

38,946

 

Gross profit

 

23,473

 

 

 

10,586

 

 

 

39,972

 

 

 

23,417

 

Operating expenses

 

 

 

 

 

 

 

Research and development

 

26,737

 

 

 

12,432

 

 

 

51,487

 

 

 

24,562

 

Sales and marketing

 

19,483

 

 

 

10,597

 

 

 

38,338

 

 

 

21,250

 

General and administrative

 

19,893

 

 

 

11,824

 

 

 

40,501

 

 

 

20,139

 

Total operating expenses

 

66,113

 

 

 

34,853

 

 

 

130,326

 

 

 

65,951

 

Loss from operations

 

(42,640

)

 

 

(24,267

)

 

 

(90,354

)

 

 

(42,534

)

Interest expense

 

 

 

 

(2,611

)

 

 

 

 

 

(5,138

)

Change in fair value of convertible notes and warrant liabilities

 

2,112

 

 

 

6,769

 

 

 

5,388

 

 

 

(1,257

)

Other income (expense), net

 

1,153

 

 

 

(84

)

 

 

1,545

 

 

 

(261

)

Total other income (expense), net

 

3,265

 

 

 

4,074

 

 

 

6,933

 

 

 

(6,656

)

Loss before provision for income taxes

 

(39,375

)

 

 

(20,193

)

 

 

(83,421

)

 

 

(49,190

)

Provision for income taxes

 

154

 

 

 

170

 

 

 

468

 

 

 

428

 

Net loss

$

(39,529

)

 

$

(20,363

)

 

$

(83,889

)

 

$

(49,618

)

Basic net loss per share attributable to common stockholders

$

(0.15

)

 

$

(0.44

)

 

$

(0.32

)

 

$

(1.08

)

Diluted net loss per share attributable to common stockholders

$

(0.15

)

 

$

(0.46

)

 

$

(0.32

)

 

$

(1.08

)

Basic weighted-average common shares outstanding used in computing net loss per share attributable to common stockholders

 

266,212,489

 

 

 

46,200,078

 

 

 

265,168,341

 

 

 

45,965,201

 

Diluted weighted-average common shares outstanding used in computing net loss per share attributable to common stockholders

 

266,212,489

 

 

 

46,693,805

 

 

 

265,168,341

 

 

 

45,965,201

 

PLANET

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)

 

 

Three Months Ended July 31,

 

Six Months Ended July 31,

(In thousands)

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Net loss

$

(39,529

)

 

$

(20,363

)

 

$

(83,889

)

 

$

(49,618

)

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

142

 

 

 

(78

)

 

 

317

 

 

 

196

 

Change in fair value of available-for-sale securities

 

303

 

 

 

 

 

 

303

 

 

 

 

Other comprehensive income (loss), net of tax

 

445

 

 

 

(78

)

 

 

620

 

 

 

196

 

Comprehensive loss

$

(39,084

)

 

$

(20,441

)

 

$

(83,269

)

 

$

(49,422

)

PLANET

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

 

 

Six Months Ended July 31,

(In thousands)

 

2022

 

 

 

2021

 

Operating activities

 

 

 

Net loss

$

(83,889

)

 

$

(49,618

)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

Depreciation and amortization

 

23,213

 

 

 

22,516

 

Stock-based compensation, net of capitalized cost

 

40,403

 

 

 

7,976

 

Change in fair value of convertible notes and warrant liabilities

 

(5,388

)

 

 

1,257

 

Deferred income taxes

 

(58

)

 

 

218

 

Amortization of debt discount and issuance costs

 

 

 

 

1,544

 

Other

 

543

 

 

 

(65

)

Changes in operating assets and liabilities

 

 

 

Accounts receivable

 

18,595

 

 

 

30,769

 

Prepaid expenses and other assets

 

(4,432

)

 

 

(5,378

)

Accounts payable, accrued and other liabilities

 

(1,866

)

 

 

(6,515

)

Deferred revenue

 

(15,165

)

 

 

(17,499

)

Deferred hosting costs

 

(760

)

 

 

7,507

 

Deferred rent

 

 

 

 

(1,015

)

Net cash used in operating activities

 

(28,804

)

 

 

(8,303

)

Investing activities

 

 

 

Purchases of property and equipment

 

(6,509

)

 

 

(4,000

)

Capitalized internal-use software

 

(1,271

)

 

 

(1,922

)

Purchases of available-for-sale securities

 

(195,113

)

 

 

 

Other

 

(293

)

 

 

(300

)

Net cash used in investing activities

 

(203,186

)

 

 

(6,222

)

Financing activities

 

 

 

Proceeds from the exercise of common stock options

 

6,418

 

 

 

3,880

 

Class A common stock withheld to satisfy employee tax withholding obligations

 

(2,164

)

 

 

 

Proceeds from the early exercise of common stock options

 

 

 

 

17,928

 

Payment of transaction costs related to the Business Combination

 

(326

)

 

 

(2,237

)

Other

 

122

 

 

 

 

Net cash provided by financing activities

 

4,050

 

 

 

19,571

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

(1,118

)

 

 

(425

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

(229,058

)

 

 

4,621

 

Cash, cash equivalents and restricted cash at the beginning of the period

 

496,814

 

 

 

76,540

 

Cash, cash equivalents and restricted cash at the end of the period

$

267,756

 

 

$

81,161

 

PLANET

RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (unaudited)

 

 

Three Months Ended July 31,

 

Six Months Ended July 31,

(in thousands)

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Net loss

$

(39,529

)

 

$

(20,363

)

 

$

(83,889

)

 

$

(49,618

)

Interest expense

 

 

 

 

2,611

 

 

 

 

 

 

5,138

 

Interest income

 

(1,311

)

 

 

 

 

 

(1,423

)

 

 

(4

)

Income tax provision

 

154

 

 

 

170

 

 

 

468

 

 

 

428

 

Depreciation and amortization

 

11,588

 

 

 

11,041

 

 

 

23,213

 

 

 

22,516

 

Change in fair value of convertible notes and warrant liabilities

 

(2,112

)

 

 

(6,769

)

 

 

(5,388

)

 

 

1,257

 

Stock-based compensation

 

20,581

 

 

 

4,874

 

 

 

40,403

 

 

 

7,976

 

Other (income) expense

 

158

 

 

 

84

 

 

 

(122

)

 

 

265

 

Adjusted EBITDA

$

(10,471

)

 

$

(8,352

)

 

$

(26,738

)

 

$

(12,042

)

PLANET

RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES (unaudited)

 

 

Three Months Ended July 31,

 

Six Months Ended July 31,

(In thousands)

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Reconciliation of cost of revenue:

 

 

 

 

 

 

 

GAAP cost of revenue

$

24,977

 

 

$

19,820

 

 

$

48,605

 

 

$

38,946

 

Less: Stock-based compensation

 

1,357

 

 

 

228

 

 

 

2,676

 

 

 

462

 

Less: Amortization of acquired intangible assets

 

366

 

 

 

 

 

 

797

 

 

 

 

Non-GAAP cost of revenue

$

23,254

 

 

$

19,592

 

 

$

45,132

 

 

$

38,484

 

 

 

 

 

 

 

 

 

Reconciliation of gross profit:

 

 

 

 

 

 

 

GAAP gross profit

$

23,473

 

 

$

10,586

 

 

$

39,972

 

 

$

23,417

 

Add: Stock-based compensation

 

1,357

 

 

 

228

 

 

 

2,676

 

 

 

462

 

Add: Amortization of acquired intangible assets

 

366

 

 

 

 

 

 

797

 

 

 

 

Non-GAAP gross profit

$

25,196

 

 

$

10,814

 

 

$

43,445

 

 

$

23,879

 

GAAP gross margin

 

48

%

 

 

35

%

 

 

45

%

 

 

38

%

Non-GAAP gross margin

 

52

%

 

 

36

%

 

 

49

%

 

 

38

%

 

 

 

 

 

 

 

 

Reconciliation of operating expenses:

 

 

 

 

 

 

 

GAAP research and development

$

26,737

 

 

$

12,432

 

 

$

51,487

 

 

$

24,562

 

Less: Stock-based compensation

 

8,503

 

 

 

1,292

 

 

 

16,732

 

 

 

2,348

 

Less: Amortization of acquired intangible assets

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP research and development

$

18,234

 

 

$

11,140

 

 

$

34,755

 

 

$

22,214

 

GAAP sales and marketing

$

19,483

 

 

$

10,597

 

 

$

38,338

 

 

$

21,250

 

Less: Stock-based compensation

 

3,757

 

 

 

646

 

 

 

7,394

 

 

 

1,282

 

Less: Amortization of acquired intangible assets

 

153

 

 

 

 

 

 

305

 

 

 

 

Non-GAAP sales and marketing

$

15,573

 

 

$

9,951

 

 

$

30,639

 

 

$

19,968

 

GAAP general and administrative

$

19,893

 

 

$

11,824

 

 

$

40,501

 

 

$

20,139

 

Less: Stock-based compensation

 

6,964

 

 

 

2,708

 

 

 

13,601

 

 

 

3,884

 

Less: Amortization of acquired intangible assets

 

80

 

 

 

363

 

 

 

160

 

 

 

726

 

Non-GAAP general and administrative

$

12,849

 

 

$

8,753

 

 

$

26,740

 

 

$

15,529

 

 

 

 

 

 

 

 

 

Reconciliation of loss from operations

 

 

 

 

 

 

 

GAAP loss from operations

$

(42,640

)

 

$

(24,267

)

 

$

(90,354

)

 

$

(42,534

)

Add: Stock-based compensation

 

20,581

 

 

 

4,874

 

 

 

40,403

 

 

 

7,976

 

Add: Amortization of acquired intangible assets

 

599

 

 

 

363

 

 

 

1,262

 

 

 

726

 

Non-GAAP loss from operations

$

(21,460

)

 

$

(19,030

)

 

$

(48,689

)

 

$

(33,832

)

PLANET

RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES (unaudited)

 

 

Three Months Ended July 31,

 

Six Months Ended July 31,

(In thousands, except share and per share amounts)

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Reconciliation of net loss

 

 

 

 

 

 

 

GAAP net loss

$

(39,529

)

 

$

(20,363

)

 

$

(83,889

)

 

$

(49,618

)

Add: Stock-based compensation

 

20,581

 

 

 

4,874

 

 

 

40,403

 

 

 

7,976

 

Add: Amortization of acquired intangible assets

 

599

 

 

 

363

 

 

 

1,262

 

 

 

726

 

Income tax effect of non-GAAP adjustments

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP net loss

$

(18,349

)

 

$

(15,126

)

 

$

(42,224

)

 

$

(40,916

)

 

 

 

 

 

 

 

 

Reconciliation of net loss per share, diluted

 

 

 

 

 

 

 

GAAP net loss, basic

$

(39,529

)

 

$

(20,363

)

 

$

(83,889

)

 

$

(49,618

)

Less: Change in fair value of dilutive warrant liabilities (1)

 

 

 

 

(1,242

)

 

 

 

 

 

 

GAAP net loss, diluted (1)

$

(39,529

)

 

$

(21,605

)

 

$

(83,889

)

 

$

(49,618

)

 

 

 

 

 

 

 

 

Non-GAAP net loss, basic

$

(18,349

)

 

$

(15,126

)

 

$

(42,224

)

 

$

(40,916

)

Less: Change in fair value of dilutive warrant liabilities (1)

 

 

 

 

(1,242

)

 

 

 

 

 

 

Non-GAAP net loss, diluted (1)

$

(18,349

)

 

$

(16,368

)

 

$

(42,224

)

 

$

(40,916

)

 

 

 

 

 

 

 

 

GAAP net loss per share, diluted

$

(0.15

)

 

$

(0.46

)

 

$

(0.32

)

 

$

(1.08

)

Add: Stock-based compensation

 

0.08

 

 

 

0.10

 

 

 

0.15

 

 

 

0.17

 

Add: Amortization of acquired intangible assets

 

 

 

 

0.01

 

 

 

 

 

 

0.02

 

Income tax effect of non-GAAP adjustments

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP net loss per share, diluted (2)

$

(0.07

)

 

$

(0.35

)

 

$

(0.16

)

 

$

(0.89

)

 

 

 

 

 

 

 

 

Weighted-average shares used in computing GAAP net loss per share, diluted (1)

 

266,212,489

 

 

 

46,693,805

 

 

 

265,168,341

 

 

 

45,965,201

 

Weighted-average shares used in computing Non-GAAP net loss per share, diluted (1)

 

266,212,489

 

 

 

46,693,805

 

 

 

265,168,341

 

 

 

45,965,201

 

 

 

 

 

 

 

 

 

(1) Diluted net loss per share adjusts basic net loss per share for the potentially dilutive impact of stock options and warrants. For warrants that are liability-classified, during periods when the impact is dilutive, the Company assumes share settlement of the instruments as of the beginning of the reporting period and adjusts the numerator to remove the change in fair value of the warrant liability and adjusts the denominator to include the dilutive shares calculated using the treasury stock method.

(2) Totals may not sum due to rounding. Figures are calculated based upon the respective underlying non-rounded data.

 

Investor Contacts

Chris Genualdi

Planet Labs PBC

[email protected]

Press Contacts

Megan Zaroda

Planet Labs PBC

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Satellite Networks Hardware Data Management Technology Apps/Applications Mobile/Wireless Other Technology

MEDIA:

Logo
Logo

SeaChange Reports Fiscal 2Q 2023 Financial and Operational Results

  • Revenue of $7.3M for Fiscal 2Q 2023 was up 12% y/y and 9% sequentially
  • Gross Margin up 200 basis points y/y to 65% with execution on profitable growth
  • Attractive outlook with focus on streaming, digital advertising, and Connected TV

BOSTON, Sept. 12, 2022 (GLOBE NEWSWIRE) — SeaChange International, Inc. (NASDAQ: SEAC), (“SeaChange” or the “Company”) a leading provider of video delivery, advertising, streaming platforms, and emerging FAST (Free Ad-Supported Streaming TV services) development, today, reported financial and operational results for the fiscal second quarter ended July 31, 2022.

Fiscal Second Quarter 2023 and Recent Highlights

  • Grew revenue year-over-year and sequentially to $7.3 million, as SeaChange continues to capture its growth opportunities in both products and services
  • Generated positive non-GAAP operating income, driven by revenue growth and cost containment as it executes upon the path to a sustainable profitable business model
  • Onboarding additional StreamVid customers, three of which are set to launch by Fiscal 4Q 2023, providing opportunity for SaaS-based and higher-margin recurring revenue
  • Closed deal with large network content owner to expand services and support live streaming of FIFA World Cup 2022
  • Renewed and extended contract with Tier 1 operator in Latin America
  • $14.3 million in cash, and no debt at quarter end

Management Commentary

“We have made great progress in the first half of fiscal 2023 in advancing our pursuit to becoming a leading technology provider that enables video distribution and monetization, while also generating improved financial results,” said SeaChange’s Chairman and Chief Executive Officer Peter D. Aquino. “We are continuing to grow our existing customer engagements, while expanding our services and offerings with new logos in high growth international markets that offer SaaS-based recurring revenue streams. We are leveraging our expertise in software engineering related to video and ad insertion services on Connected TVs and streaming devices. Additionally, we are encouraged by our continued revenue growth and positive non-GAAP operating income, which solidifies our platform for further market expansion through organic growth, and potential strategic alternatives to gain scale.”

Fiscal Second Quarter 2023 Financial Results

  • Total revenue was $7.3 million, an increase of 9% compared to $6.7 million in the first quarter of fiscal 2023 and an increase of 12% compared to $6.5 million in the second quarter of fiscal 2022. The sequential increase was primarily due to higher product and services revenue.
  • Product revenue was $3.0 million (or 41% of total revenue), compared to $2.8 million (or 42% of total revenue) in the first quarter of fiscal 2023 and $2.7 million (or 41% of total revenue) in the second quarter of fiscal 2022. Service revenue was $4.3 million (or 59% of total revenue) compared to $3.9 million (or 58% of total revenue) in the first quarter of fiscal 2023 and $3.8 million (or 59% of total revenue) in the second quarter of fiscal 2022.
  • Gross profit was $4.8 million (or 65% of total revenue), an increase of 48% compared to $3.2 million (or 48% of total revenue) in the first quarter of fiscal 2023 and an increase of 16% compared to $4.1 million (or 63% of total revenue) in the second quarter of fiscal 2022.
  • Total non-GAAP operating expenses were $4.7 million, compared to non-GAAP operating expenses of $4.7 million in the first quarter of fiscal 2023 and $5.4 million in the second quarter of fiscal 2022.
  • GAAP loss from operations totaled $6.5 million, compared to a GAAP loss from operations of $2.7 million in the first quarter of fiscal 2023 and $2.5 million in the second quarter of fiscal 2022. GAAP loss from operations in the second quarter of fiscal 2023 included a $5.8 million non-cash goodwill impairment.
  • GAAP net loss totaled $6.5 million, or $(0.13) per basic share, compared to a GAAP net loss of $3.0 million, or $(0.06) per basic share, in the first quarter of fiscal 2023 and a GAAP net income of $0.2 million, or $0.00 per fully diluted share, in the second quarter of fiscal 2022.
  • Non-GAAP income from operations totaled $11,000, or $0.00 per fully diluted share, compared to non-GAAP loss from operations of $1.5 million, or $(0.03) per basic share, in the first quarter of fiscal 2023, and non-GAAP loss from operations of $1.3 million, or $(0.03) per basic share, in the second quarter of fiscal 2022.
  • Ended the second quarter of fiscal 2023 with cash and cash equivalents of $14.3 million and no debt.

Conference Call

There will be a conference call today (September 12, 2022) at 4:30 p.m. Eastern Time to discuss these results.

U.S. dial-in number: 877-407-8037
International number: +1 201-689-8037
Meeting Number: 13732613

Please call the conference telephone number approximately 10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 949-574-3860.

The conference call will be broadcast and available for replay here and via the investor relations section of SeaChange’s website.

About SeaChange International, Inc.

SeaChange International, Inc. (NASDAQ: SEAC) provides first-class video streaming, linear TV, and video advertising technology for operators, content owners, and broadcasters globally. SeaChange’s technology enables operators, broadcasters, and content owners to cost-effectively launch and grow premium linear TV and direct-to-consumer streaming services to manage, curate, and monetize their content. SeaChange helps protect existing and develop new and incremental advertising revenues for traditional linear TV and streaming services with its unique advertising technology. SeaChange enjoys a rich heritage of nearly three decades of delivering premium video software solutions to its global customer base.

Safe Harbor Provision

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. Forward-looking statements can be identified by words such as “may,” “might,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “seeks,” “intends,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. Examples of forward-looking statements include, among others, statements we make regarding the Company’s ability to onboard additional StreamVid customers, to continue to grow our existing customer engagements, to expand our market through organic growth, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of the Company and are subject to a number of known and unknown risks and significant business, economic and competitive uncertainties that could cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. Risks that could cause actual results to differ include, but are not limited to: the impact of COVID-19 on our business and the economies in which we operate; the impact of the ongoing conflict in Ukraine on our business; the continued spending by the Company’s customers on video solutions and services and expenses we may incur in fulfilling customer arrangements; the increase in service and supply costs, including as a result of inflationary pressures; the manner in which the multiscreen video and over-the-top markets develop; the Company’s ability to compete in the software marketplace; the loss of or reduction in demand, or the return of product, by one of the Company’s large customers or the failure of revenue acceptance criteria in a given fiscal quarter; the cancellation or deferral of purchases of the Company’s products; any decline in demand or average selling prices for our products and services; failure to achieve our financial forecasts due to inaccurate sales forecasts or other factors, including due to expenses we may incur in fulfilling customer arrangements; the impact of our cost-savings and restructuring programs; the Company’s ability to manage its growth; the risks associated with international operations; the ability of the Company to use its net operating losses; the impact of changes in the market on the value of our investments; changes in the regulatory environment; the ability of SeaChange to remain listed on Nasdaq; the success and timing of regulatory submissions; regulatory requirements or developments; and other risks that are described in further detail in the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), which are available at the SEC’s website at http://www.sec.gov, including but not limited to, such information appearing under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K, subsequent quarterly reports and in other filings SeaChange makes with the SEC from time to time. Any forward-looking statements should be considered in light of those risk factors. The Company cautions readers that such forward-looking statements speak only as of the date they are made. The Company disclaims any intent or obligation to publicly update or revise any such forward-looking statements to reflect any change in Company expectations or future events, conditions or circumstances on which any such forward-looking statements may be based, or that may affect the likelihood that actual results may differ from those set forth in such forward-looking statements.

SeaChange Contact:

Matt Glover and Jeff Grampp, CFA
Gateway Group, Inc.
949-574-3860
[email protected]

SeaChange International, Inc.

Condensed Consolidated Balance Sheets

(Amounts in thousands)

    July 31, 2022     January 31, 2022  
Assets            
Cash and cash equivalents   $ 14,336     $ 17,528  
Accounts and other receivables, net     6,654       8,819  
Unbilled receivables     14,339       13,112  
Prepaid expenses and other current assets     2,671       2,310  
Property and equipment, net     714       902  
Goodwill and intangible assets, net     3,364       9,882  
Other assets     1,998       2,643  
Total assets   $ 44,076     $ 55,196  
Liabilities and Stockholders’ Equity            
Accounts payable and other liabilities   $ 7,230     $ 8,538  
Deferred revenue     4,169       4,024  
Income taxes payable     110       110  
Total liabilities     11,509       12,672  
Total stockholders’ equity     32,567       42,524  
Total liabilities and stockholders’ equity   $ 44,076     $ 55,196  



SeaChange International, Inc.

Consolidated Statements of Operations (Unaudited)

(Amounts in thousands, except per share data)

    For the Three Months

Ended July 31,
    For the Six Months

Ended July 31,
 
    2022     2021     2022     2021  
Revenue:                        
Product   $ 2,986     $ 2,709     $ 5,812     $ 4,329  
Service     4,338       3,831       8,235       7,263  
Total revenue     7,324       6,540       14,047       11,592  
Cost of revenue:                        
Product     847       693       2,492       1,099  
Service     1,718       1,730       3,576       3,545  
Total cost of revenue     2,565       2,423       6,068       4,644  
Gross profit     4,759       4,117       7,979       6,948  
Operating expenses:                        
Research and development     1,956       2,213       3,663       4,881  
Selling and marketing     934       1,643       1,916       3,023  
General and administrative     2,108       2,682       4,394       4,787  
Severance and restructuring costs     28       87       193       571  
Transaction costs     382             1,198        
Loss on impairment of goodwill     5,843             5,843        
Total operating expenses     11,251       6,625       17,207       13,262  
Loss from operations     (6,492 )     (2,508 )     (9,228 )     (6,314 )
Other income (expense), net     36       212       (223 )     (16 )
Gain on extinguishment of debt           2,440             2,440  
(Loss) income before income taxes     (6,456 )     144       (9,451 )     (3,890 )
Income tax benefit     5       83       4       49  
Net (loss) income   $ (6,451 )   $ 227     $ (9,447 )   $ (3,841 )
Net (loss) income per share, basic   $ (0.13 )   $ 0.00     $ (0.19 )   $ (0.09 )
Net (loss) income per share, diluted   $ (0.13 )   $ 0.00     $ (0.19 )   $ (0.09 )
Weighted average common shares outstanding, basic     49,463       48,489       49,341       44,958  
Weighted average common shares outstanding, diluted     49,463       48,727       49,341       44,958  
Comprehensive loss:                        
Net (loss) income   $ (6,451 )   $ 227     $ (9,447 )   $ (3,841 )
Other comprehensive loss, net of tax:                        
Foreign currency translation adjustment     (475 )     (399 )     (1,051 )     (358 )
Unrealized gains on marketable securities                       1  
Total other comprehensive loss     (475 )     (399 )     (1,051 )     (357 )
Comprehensive loss   $ (6,926 )   $ (172 )   $ (10,498 )   $ (4,198 )

SeaChange International, Inc.

Consolidated Statements of Cash Flows (Unaudited)

(Amounts in thousands)

    For the Six Months

Ended July 31,
 
    2022     2021  
Cash flows from operating activities:            
Net loss   $ (9,447 )   $ (3,841 )
Adjustments to reconcile net loss to net cash used in operating activities:            
Depreciation and amortization expense     133       732  
Loss on disposal of fixed assets           77  
Gain on write-off of operating lease right-of-use assets and liabilities related to termination           (328 )
Gain on extinguishment of debt           (2,440 )
Change in allowance for doubtful accounts     256       (135 )
Stock-based compensation expense     534       1,041  
Realized and unrealized foreign currency transaction loss     402       201  
Loss on impairment of goodwill     5,843        
Other           1  
Changes in operating assets and liabilities:            
Accounts receivable     1,893       579  
Unbilled receivables, net     (1,635 )     1,208  
Prepaid expenses and other current assets and other assets     (50 )     354  
Accounts payable     (868 )     (527 )
Accrued expenses and other liabilities     119       (170 )
Deferred revenue     218       (1,085 )
Net cash used in operating activities     (2,602 )     (4,333 )
Cash flows from investing activities:            
Purchases of property and equipment     (20 )     (77 )
Proceeds from sales and maturities of marketable securities           252  
Net cash (used in) provided by investing activities     (20 )     175  
Cash flows from financing activities:            
Proceeds from stock option exercises           137  
Proceeds from issuance of common stock, net of issuance costs           17,462  
Proceeds from short swing profit settlement     7        
Net cash provided by financing activities     7       17,599  
Effect of exchange rate on cash, cash equivalents and restricted cash     (615 )     (242 )
Net (decrease) increase in cash, cash equivalents and restricted cash     (3,230 )     13,199  
Cash, cash equivalents and restricted cash at beginning of period     17,856       6,084  
Cash, cash equivalents and restricted cash at end of period   $ 14,626     $ 19,283  
Supplemental disclosure of cash flow information            
Income tax payments, net   $ 160     $ 109  

Non-GAAP Measures

We define non-GAAP loss from operations as U.S. GAAP net loss plus stock-based compensation expenses, amortization of intangible assets, severance and restructuring costs, transaction costs, goodwill impairment charges, other expense, net, and income tax provision. We discuss non-GAAP loss from operations, including on a per share basis, in our quarterly earnings releases and certain other communications, as we believe non-GAAP operating loss from operations is an important measure that is not calculated according to U.S. GAAP. We use non-GAAP loss from operations in internal forecasts and models when establishing internal operating budgets, supplementing the financial results and forecasts reported to our Board of Directors, determining a component of bonus compensation for executive officers and other key employees based on operating performance, and evaluating short-term and long-term operating trends in our operations. We believe that the non-GAAP loss from operations financial measure assists in providing an enhanced understanding of our underlying operational measures to manage the business, to evaluate performance compared to prior periods and the marketplace, and to establish operational goals. We believe that the non-GAAP financial adjustments are useful to investors because they allow investors to evaluate the effectiveness of the methodology and information used by management in our financial and operational decision-making.

Non-GAAP loss from operations is a non-GAAP financial measure and should not be considered in isolation or as a substitute for financial information provided in accordance with U.S. GAAP. This non-GAAP financial measure may not be computed in the same manner as similarly titled measures used by other companies. We expect to continue to incur expenses similar to the financial adjustments described above in arriving at non-GAAP loss from operations and investors should not infer from our presentation of this non-GAAP financial measure that these costs are unusual, infrequent or non-recurring. The following table includes the reconciliations of our U.S. GAAP loss from operations, the most directly comparable U.S. GAAP financial measure, to our non-GAAP loss from operations for the three and six months ended July 31, 2022.



SeaChange International, Inc.

Fiscal Year Reconciliation of GAAP to Non-GAAP (Unaudited)

(Amounts in thousands, except per share data)

    For the Three Months

Ended July 31,
    For the Six Months

Ended July 31,
 
    2022     2021     2022     2021  
             
GAAP net (loss) income   $ (6,451 )   $ 227     $ (9,447 )   $ (3,841 )
Other (income) expense, net     (36 )     (212 )     223       16  
Gain on extinguishment of debt           (2,440 )           (2,440 )
Income tax benefit     (5 )     (83 )     (4 )     (49 )
GAAP loss from operations   $ (6,492 )   $ (2,508 )   $ (9,228 )   $ (6,314 )
Amortization of intangible assets           316             632  
Stock-based compensation     250       833       534       1,041  
Severance and restructuring costs     28       87       193       571  
Transaction costs     382             1,198        
Loss on impairment of goodwill     5,843             5,843        
Non-GAAP income (loss) from operations   $ 11     $ (1,272 )   $ (1,460 )   $ (4,070 )
                         
GAAP net (loss) income per share, basic and diluted   $ (0.13 )   $     $ (0.19 )   $ (0.09 )
GAAP loss from operations per share, basic and diluted   $ (0.13 )   $ (0.05 )   $ (0.19 )   $ (0.14 )
Non-GAAP income (loss) from operations per share, basic and diluted   $     $ (0.03 )   $ (0.03 )   $ (0.09 )
Weighted average common shares outstanding, basic     49,463       48,489       49,341       44,958  
Weighted average common shares outstanding, diluted     49,463       48,727       49,341       44,958  



SeaChange International, Inc.

Supplemental Schedule – Revenue Breakout (Unaudited)

(Amounts in thousands)

    For the Three Months

Ended July 31,
    For the Six Months

Ended July 31,
 
    2022     2021     2022     2021  
             
Product revenue:                        
License and subscription   $ 2,776     $ 2,514     $ 3,998     $ 4,134  
Hardware     210       195       1,814       195  
Total product revenue     2,986       2,709       5,812       4,329  
Service revenue:                        
Maintenance and support     3,288       3,306       6,227       6,283  
Professional services and other     1,050       525       2,008       980  
Total service revenue     4,338       3,831       8,235       7,263  
Total revenue   $ 7,324     $ 6,540     $ 14,047     $ 11,592  



First Trust/abrdn Emerging Opportunity Fund Declares its Quarterly Distribution of $0.25 Per Share

First Trust/abrdn Emerging Opportunity Fund Declares its Quarterly Distribution of $0.25 Per Share

WHEATON, Ill.–(BUSINESS WIRE)–
First Trust/abrdn Emerging Opportunity Fund (the “Fund”) (NYSE: FEO) has declared the Fund’s regularly scheduled quarterly distribution of $0.25 per share. The distribution will be payable on September 30, 2022, to shareholders of record as of September 23, 2022. The ex-dividend date is expected to be September 22, 2022. The quarterly distribution information for the Fund appears below.

First Trust/abrdn Emerging Opportunity Fund (FEO):

 

Distribution per share:

$0.25

Distribution Rate based on the September 9, 2022 NAV of $10.03:

9.97%

Distribution Rate based on the September 9, 2022 closing market price of $8.89:

11.25%

The Fund’s Board of Trustees has approved a managed distribution policy for the Fund (the “Plan”) in reliance on exemptive relief received from the Securities and Exchange Commission which permits the Fund to make periodic distributions of long-term capital gains more frequently than otherwise permitted with respect to its common shares subject to certain conditions. Under the Plan, the Fund intends to pay a quarterly distribution in the amount of $0.25 per share. A portion of this quarterly distribution may include long-term capital gains. This may result in a reduction of the long-term capital gain distribution necessary at year end by distributing realized capital gains throughout the year. The annual distribution rate is independent of the Fund’s performance during any particular period but is expected to correlate with the Fund’s performance over time. Accordingly, you should not draw any conclusions about the Fund’s investment performance from the amount of any distribution or from the terms of the Plan.

This distribution will consist of net investment income earned by the Fund and may also consist of return of capital and/or realized capital gains. The final determination of the source and tax status of all distributions paid in 2022 will be made after the end of 2022 and will be provided on Form 1099-DIV.

The Fund is a closed-end management investment company that seeks to provide a high level of total return. The Fund seeks to achieve its investment objective by investing at least 80% of its managed assets in a diversified portfolio of equity and fixed-income securities of issuers in emerging market countries.

First Trust Advisors L.P. (“FTA”) is a federally registered investment advisor and serves as the Fund’s investment advisor. FTA and its affiliate First Trust Portfolios L.P. (“FTP”), a FINRA registered broker-dealer, are privately-held companies that provide a variety of investment services. FTA has collective assets under management or supervision of approximately $193 billion as of August 31, 2022 through unit investment trusts, exchange-traded funds, closed-end funds, mutual funds and separate managed accounts. FTA is the supervisor of the First Trust unit investment trusts, while FTP is the sponsor. FTP is also a distributor of mutual fund shares and exchange-traded fund creation units. FTA and FTP are based in Wheaton, Illinois.

abrdn Inc. (formerly Aberdeen Standard Investments Inc.) (“abrdn”) serves as the Fund’s investment sub-advisor. abrdn is an indirect wholly-owned subsidiary of abrdn plc. abrdn is the brand name for the asset management group of abrdn plc, managing approximately $469.2 billion in assets as of June 30, 2022 for a range of pension funds, financial institutions, investment trusts, unit trusts, offshore funds, charities and private clients.

Principal Risk Factors: Risks are inherent in all investing. Certain risks applicable to the Fund are identified below, which includes the risk that you could lose some or all of your investment in the Fund. The principal risks of investing in the Fund are spelled out in the Fund’s annual shareholder reports. The order of the below risk factors does not indicate the significance of any particular risk factor. The Fund also files reports, proxy statements and other information that is available for review.

Past performance is no assurance of future results. Investment return and market value of an investment in the Fund will fluctuate. Shares, when sold, may be worth more or less than their original cost. There can be no assurance that the Fund’s investment objectives will be achieved. The Fund may not be appropriate for all investors.

Securities held by a fund, as well as shares of a fund itself, are subject to market fluctuations caused by factors such as general economic conditions, political events, regulatory or market developments, changes in interest rates and perceived trends in securities prices. Shares of a fund could decline in value or underperform other investments as a result of the risk of loss associated with these market fluctuations. In addition, local, regional or global events such as war, acts of terrorism, spread of infectious diseases or other public health issues, recessions, or other events could have a significant negative impact on a fund and its investments. Such events may affect certain geographic regions, countries, sectors and industries more significantly than others. In February 2022, Russia invaded Ukraine which has caused and could continue to cause significant market disruptions and volatility within the markets in Russia, Europe, and the United States. The hostilities and sanctions resulting from those hostilities could have a significant impact on certain fund investments as well as fund performance. The outbreak of the respiratory disease designated as COVID-19 in December 2019 has caused significant volatility and declines in global financial markets, which have caused losses for investors. While the development of vaccines has slowed the spread of the virus and allowed for the resumption of “reasonably” normal business activity in the United States, many countries continue to impose lockdown measures in an attempt to slow the spread. Additionally, there is no guarantee that vaccines will be effective against emerging variants of the disease.

Shares of closed-end investment companies such as the Fund frequently trade at a discount from their net asset value. The Fund cannot predict whether its common shares will trade at, below or above net asset value.

The debt securities in which the Fund invests are subject to certain risks, including issuer risk, reinvestment risk, prepayment risk, credit risk, and interest rate risk. Issuer risk is the risk that the value of fixed-income securities may decline for a number of reasons which directly relate to the issuer. Reinvestment risk is the risk that income from the Fund’s portfolio will decline if the Fund invests the proceeds from matured, traded or called bonds at market interest rates that are below the Fund portfolio’s current earnings rate. Prepayment risk is the risk that, upon a prepayment, the actual outstanding debt on which the Fund derives interest income will be reduced. Credit risk is the risk that an issuer of a security will be unable or unwilling to make dividend, interest and/or principal payments when due and that the value of a security may decline as a result. Interest rate risk is the risk that fixed-income securities will decline in value because of changes in market interest rates.

Asset-backed securities are subject to credit risk, extension risk, interest rate risk, liquidity risk, prepayment risk and valuation risk, as well as risk of default on the underlying assets.

The value of the Fund’s shares will fluctuate with changes in the value of the equity securities in which the Fund invests. Prices of equity securities fluctuate for several reasons.

The Fund invests in non-investment grade debt instruments, commonly referred to as “high-yield securities”. High yield securities are subject to greater market fluctuations and risk of loss than securities with higher ratings. Lower-quality debt tends to be less liquid than higher-quality debt.

Credit ratings are determined by credit rating agencies and are only the opinions of such entities. Ratings assigned by a rating agency are not absolute standards of credit quality and do not evaluate market risk or the liquidity of securities.

Credit default swap transactions involve greater risks than if the Fund had invested in the reference obligation directly.

Credit linked notes are securities that are collateralized by one or more credit default swaps on designated debt securities that are referred to as “reference securities.” The market for credit linked notes may suddenly become illiquid. Changes in liquidity may result in significant, rapid and unpredictable changes in the prices for credit linked notes. In certain cases, a market price for a credit linked note may not be available.

The Fund invests in equity and debt securities of non-U.S. issuers which are subject to higher volatility than securities of U.S. issuers. Risks may be heightened for securities of companies located in, or with significant operations in, emerging market countries. Financial and other reporting by companies and government entities also may be less reliable in emerging market countries. Shareholder claims that are available in the U.S., as well as regulatory oversight and authority that is common in the U.S., including for claims based on fraud, may be difficult or impossible for shareholders of securities in emerging market countries or for U.S. authorities to pursue. Because the Fund invests in non-U.S. securities, you may lose money if the local currency of a non-U.S. market depreciates against the U.S. dollar. In addition to the risks associated with investments in non-U.S. securities generally, the Fund is subject to certain risks associated specifically with investments in securities of Chinese issuers.

Forward foreign currency exchange contracts involve certain risks, including the risk of failure of the counterparty to perform its obligations under the contract and the risk that the use of forward contracts may not serve as a complete hedge because of an imperfect correlation between movements in the prices of the contracts and the prices of the currencies hedged.

The Fund may invest from time to time a substantial amount of its assets in issuers located in a single country or region. Because the Fund may concentrate its investments in this manner, it assumes the risk that economic, political and social conditions in that country or region will have a significant impact on its investment performance, which may result in greater losses and volatility than if it had diversified its investments across a greater number of countries and regions.

To the extent a fund invests in floating or variable rate obligations that use the London Interbank Offered Rate (“LIBOR”) as a reference interest rate, it is subject to LIBOR Risk. The United Kingdom’s Financial Conduct Authority, which regulates LIBOR, will cease making LIBOR available as a reference rate over a phase-out period that began December 31, 2021. There is no assurance that any alternative reference rate, including the Secured Overnight Financing Rate (“SOFR”) will be similar to or produce the same value or economic equivalence as LIBOR or that instruments using an alternative rate will have the same volume or liquidity. The unavailability or replacement of LIBOR may affect the value, liquidity or return on certain fund investments and may result in costs incurred in connection with closing out positions and entering into new trades. Any potential effects of the transition away from LIBOR on the fund or on certain instruments in which the fund invests can be difficult to ascertain, and they may vary depending on a variety of factors, and they could result in losses to the fund.

Use of leverage can result in additional risk and cost, and can magnify the effect of any losses.

The risks of investing in the Fund are spelled out in the shareholder report and other regulatory filings.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.

The Fund’s daily closing New York Stock Exchange price and net asset value per share as well as other information can be found at https://www.ftportfolios.com or by calling 1-800-988-5891.

Press Inquiries, Ryan Issakainen, 630-765-8689

Analyst Inquiries, Jeff Margolin, 630-915-6784

Broker Inquiries, Sales Team, 866-848-9727

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Banking Professional Services

MEDIA:

Logo
Logo